keyword
MENU ▼
Read by QxMD icon Read
search

Pseudoprogression

keyword
https://www.readbyqxmd.com/read/28640707/response-assessment-in-neuro-oncology-clinical-trials
#1
Patrick Y Wen, Susan M Chang, Martin J Van den Bent, Michael A Vogelbaum, David R Macdonald, Eudocia Q Lee
Development of novel therapies for CNS tumors requires reliable assessment of response and progression. This requirement has been particularly challenging in neuro-oncology for which contrast enhancement serves as an imperfect surrogate for tumor volume and is influenced by agents that affect vascular permeability, such as antiangiogenic therapies. In addition, most tumors have a nonenhancing component that can be difficult to accurately quantify. To improve the response assessment in neuro-oncology and to standardize the criteria that are used for different CNS tumors, the Response Assessment in Neuro-Oncology (RANO) working group was established...
June 22, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28621686/pseudoprogression-in-microsatellite-instability-high-colorectal-cancer-during-treatment-with-combination-t-cell-mediated-immunotherapy-a-case-report-and-literature-review
#2
Young Kwang Chae, Si Wang, Halla Nimeiri, Aparna Kalyan, Francis J Giles
Evading tumor-mediated immunosuppression through antibodies to immune checkpoints has shown clinical benefit in patients with select solid tumors. There is a heterogeneity of responses in patients receiving immunotherapy, including pseudoprogression in which the tumor burden increases initially before decreasing to reach disease control. The characteristics and basis of pseudoprogression, however, remains poorly understood. We hereby report a case of microsatellite instability (MSI)-high metastatic colorectal cancer treated with combination of OX40 agonist and programmed death ligand-1 (PD-L1) antagonist that demonstrated pseudoprogression reaching 163% increase from baseline tumor burden...
June 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/28592629/immune-related-tumor-response-dynamics-in-melanoma-patients-treated-with-pembrolizumab-identifying-markers-for-clinical-outcome-and-treatment-decisions
#3
Mizuki Nishino, Anita Giobbie-Hurder, Michael P Manos, Nancy Bailey, Elizabeth I Buchbinder, Patrick A Ott, Nikhil H Ramaiya, F Stephen Hodi
Purpose: Characterize tumor burden dynamics during PD-1 inhibitor therapy and investigate the association with overall survival (OS) in advanced melanoma.Experimental Design: The study included 107 advanced melanoma patients treated with pembrolizumab. Tumor burden dynamics were assessed on serial CT scans using irRECIST and were studied for the association with OS.Results: Among 107 patients, 96 patients had measurable tumor burden and 11 had nontarget lesions alone at baseline. In the 96 patients, maximal tumor shrinkage ranged from -100% to 567% (median, -18...
June 7, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28588582/nanoparticle-based-magnetic-resonance-imaging-on-tumor-associated-macrophages-and-inflammation
#4
REVIEW
Natalie J Serkova
The inflammatory response, mediated by tissue-resident or newly recruited macrophages, is an underlying pathophysiological condition for many diseases, including diabetes, obesity, neurodegeneration, atherosclerosis, and cancer. Paradoxically, inflammation is a double-edged sword in oncology. Macrophages are, generally speaking, the major drivers of inflammatory insult. For many solid tumors, high density of cells expressing macrophage-associated markers have generally been found in association with a poor clinical outcome, characterized by inflamed microenvironment, a high level of dissemination and resistance to conventional chemotherapies...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28536391/glioma-fmiso-pet-mr-imaging-concurrent-with-antiangiogenic-therapy-molecular-imaging-as-a-clinical-tool-in-the-burgeoning-era-of-personalized-medicine
#5
Ramon F Barajas, Kenneth A Krohn, Jeanne M Link, Randall A Hawkins, Jennifer L Clarke, Miguel H Pampaloni, Soonmee Cha
The purpose of this article is to provide a focused overview of the current use of positron emission tomography (PET) molecular imaging in the burgeoning era of personalized medicine in the treatment of patients with glioma. Specifically, we demonstrate the utility of PET imaging as a tool for personalized diagnosis and therapy by highlighting a case series of four patients with recurrent high grade glioma who underwent 18F-fluoromisonidazole (FMISO) PET/MR (magnetic resonance) imaging through the course of antiangiogenic therapy...
October 31, 2016: Biomedicines
https://www.readbyqxmd.com/read/28520730/analysis-of-heterogeneity-in-t2-weighted-mr-images-can-differentiate-pseudoprogression-from-progression-in-glioblastoma
#6
Thomas C Booth, Timothy J Larkin, Yinyin Yuan, Mikko I Kettunen, Sarah N Dawson, Daniel Scoffings, Holly C Canuto, Sarah L Vowler, Heide Kirschenlohr, Michael P Hobson, Florian Markowetz, Sarah Jefferies, Kevin M Brindle
PURPOSE: To develop an image analysis technique that distinguishes pseudoprogression from true progression by analyzing tumour heterogeneity in T2-weighted images using topological descriptors of image heterogeneity called Minkowski functionals (MFs). METHODS: Using a retrospective patient cohort (n = 50), and blinded to treatment response outcome, unsupervised feature estimation was performed to investigate MFs for the presence of outliers, potential confounders, and sensitivity to treatment response...
2017: PloS One
https://www.readbyqxmd.com/read/28512646/mri-in-glioma-immunotherapy-evidence-pitfalls-and-perspectives
#7
REVIEW
Domenico Aquino, Andrea Gioppo, Gaetano Finocchiaro, Maria Grazia Bruzzone, Valeria Cuccarini
Pseudophenomena, that is, imaging alterations due to therapy rather than tumor evolution, have an important impact on the management of glioma patients and the results of clinical trials. RANO (response assessment in neurooncology) criteria, including conventional MRI (cMRI), addressed the issues of pseudoprogression after radiotherapy and concomitant chemotherapy and pseudoresponse during antiangiogenic therapy of glioblastomas (GBM) and other gliomas. The development of cancer immunotherapy forced the identification of further relevant response criteria, summarized by the iRANO working group in 2015...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28512410/rrx-001-priming-of-pd-1-inhibition-in-the-treatment-of-small-cell-carcinoma-of-the-vagina-a-rare-gynecological-tumor
#8
Christina Brzezniak, Bryan Oronsky, Jane Trepel, Thomas A Summers, Pedro Cabrales, Min-Jung Lee, Regina Day, Saheli Jha, Scott Caroen, Karen Zeman, Lindsey Ferry, Cindy Harmer, Neil Oronsky, Michelle Lybeck, Harry E Lybeck, James F Brown, Tony R Reid, Corey A Carter
Small cell carcinoma of the vagina is rare, so rare in fact that the total number reported in English-language journals is less than 30. Due to this extremely low incidence, no specific treatment guidelines have been established, and most of what is clinically known is derived from a handful of single case reports. However, as befitting its highly aggressive histologic features, which are reminiscent of small cell lung cancer (SCLC), first-line treatment is modeled after SCLC. Herein is reported the case of a 51-year-old African-American patient with metastatic biopsy-proven small cell carcinoma of the vagina that progressed through multiple therapies: first-line cisplatin and etoposide (making it platinum-resistant) and radiotherapy, followed by the tumor macrophage-stimulating agent RRx-001 in a clinical trial called QUADRUPLE THREAT, which per protocol preceded a mandated rechallenge with cisplatin and etoposide...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28500114/pseudoprogression-in-lung-adenocarcinoma-during-treatment-with-nivolumab
#9
Toshihide Izumida, Yukio Kawagishi, Hiroshi Tsuji
No abstract text is available yet for this article.
May 12, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28486641/current-clinical-brain-tumor-imaging
#10
Javier E Villanueva-Meyer, Marc C Mabray, Soonmee Cha
Neuroimaging plays an ever evolving role in the diagnosis, treatment planning, and post-therapy assessment of brain tumors. This review provides an overview of current magnetic resonance imaging (MRI) methods routinely employed in the care of the brain tumor patient. Specifically, we focus on advanced techniques including diffusion, perfusion, spectroscopy, tractography, and functional MRI as they pertain to noninvasive characterization of brain tumors and pretreatment evaluation. The utility of both structural and physiological MRI in the post-therapeutic brain evaluation is also reviewed with special attention to the challenges presented by pseudoprogression and pseudoresponse...
May 9, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28483374/-18-f-fdg-pet-ct-in-the-clinical-management-of-patients-with-lymphoma
#11
P Tamayo, A Martín, L Díaz, M Cabrero, R García, P García-Talavera, D Caballero
The aim of this work was to review the current recommendations for staging and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in routine clinical practice after chemotherapy and/or stem cell transplantation. A five-point scale (5-PS) from the First International Workshop on PET in Lymphoma in Deauville, France, in 2009, was recommended as the standard tool to score imaging to assess treatment response in patients with lymphoma using (18)F-Fluorodeoxyglucose (FDG) PET/CT...
May 5, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/28466127/incidence-of-tumour-progression-and-pseudoprogression-in-high-grade-gliomas-a%C3%A2-systematic-review-and-meta-analysis
#12
Abdul W Abbasi, Henriette E Westerlaan, Gea A Holtman, Kamal M Aden, Peter Jan van Laar, Anouk van der Hoorn
BACKGROUND: High-grade gliomas are the most common primary brain tumours. Pseudoprogression describes the false appearance of radiation-induced progression on MRI. A distinction should be made from true tumour progression to correctly plan treatment. However, there is wide variation of reported pseudoprogression. We thus aimed to establish the incidence of pseudoprogression and tumour progression in high-grade glioma patients with a systematic review and meta-analysis. METHODS: We searched PubMed, Embase and Web of Science on the incidence of pseudoprogression and tumour progression in adult high-grade glioma patients from 2005, the latest on 8 October 2014...
May 2, 2017: Clinical Neuroradiology
https://www.readbyqxmd.com/read/28453748/incidence-of-pseudoprogression-in-low-grade-gliomas-treated-with-radiotherapy
#13
Sophie E van West, Hein G de Bruin, Bart van de Langerijt, Annemarie T Swaak-Kragten, Martin J van den Bent, Walter Taal
Background.: As the incidence of pseudo-progressive disease (psPD), or pseudoprogression, in low-grade glioma (LGG) is unknown, we retrospectively investigated this phenomenon in a cohort of LGG patients given radiotherapy (RT). Methods.: All MRI scans and clinical data from patients with histologically proven LGG treated with radiation between 2000 and 2011 were reviewed. PsPD was scored when a new enhancing lesion occurred after RT and subsequently disappeared or remained stable for at least a year without therapy, including dexamethasone...
May 1, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28428211/imaging-manifestations-of-pseudoprogression-in-metastatic-melanoma-nodes-injected-with-talimogene-laherparepvec-initial-experience
#14
C Zamora, M Lopez, F Cunningham, F Collichio, M Castillo
Talimogene laherparepvec is an oncolytic virus recently approved for targeted treatment of advanced melanoma. Because of an inflammatory reaction, treated lesions may increase in size and develop infiltrative margins that can be construed as disease progression or extracapsular spread. In this report, we describe our initial experience imaging the response of metastatic nodes injected with talimogene laherparepvec. Six of 12 nodes (50%) showed growth from baseline followed by decreased size, 5 of 12 nodes (42%) showed a downward size trend, and 1 node showed continued increase in size...
April 20, 2017: AJNR. American Journal of Neuroradiology
https://www.readbyqxmd.com/read/28384170/differentiation-of-pseudoprogression-and-real-progression-in-glioblastoma-using-adc-parametric-response-maps
#15
Caroline Reimer, Katerina Deike, Markus Graf, Peter Reimer, Benedikt Wiestler, Ralf Omar Floca, Philipp Kickingereder, Heinz-Peter Schlemmer, Wolfgang Wick, Martin Bendszus, Alexander Radbruch
PURPOSE: The purpose of this study was to investigate whether a voxel-wise analysis of apparent diffusion coefficient (ADC) values may differentiate between progressive disease (PD) and pseudoprogression (PsP) in patients with high-grade glioma using the parametric response map, a newly introduced postprocessing tool. METHODS: Twenty-eight patients with proven PD and seven patients with PsP were identified in this retrospective feasibility study. For all patients ADC baseline and follow-up maps on four subsequent MRIs were available...
2017: PloS One
https://www.readbyqxmd.com/read/28382534/pseudoprogression-radionecrosis-inflammation-or-true-tumor-progression-challenges-associated-with-glioblastoma-response-assessment-in-an-evolving-therapeutic-landscape
#16
REVIEW
Benjamin M Ellingson, Caroline Chung, Whitney B Pope, Jerrold L Boxerman, Timothy J Kaufmann
The wide variety of treatment options that exist for glioblastoma, including surgery, ionizing radiation, anti-neoplastic chemotherapies, anti-angiogenic therapies, and active or passive immunotherapies, all may alter aspects of vascular permeability within the tumor and/or normal parenchyma. These alterations manifest as changes in the degree of contrast enhancement or T2-weighted signal hyperintensity on standard anatomic MRI scans, posing a potential challenge for accurate radiographic response assessment for identifying anti-tumor effects...
April 5, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28371397/delayed-pseudoprogression-of-lung-adenocarcinoma-accompanied-with-interstitial-lung-disease-during-chemotherapy-after-nivolumab-treatment
#17
Toru Kumagai, Madoka Kimura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Fumio Imamura
A 62-year-old Japanese female with primary lung adenocarcinoma received seven cycles of nivolumab as an eighth line of chemotherapy until she presented with hemoptysis. After transcatheter arterial embolization therapy, she received subsequent chemotherapy with paclitaxel and S-1. Four weeks later, a chest computed tomography examination revealed infiltrative shadows mainly in the right lung field, in addition to enlargement of the lung metastasis in the right middle lung lobe. Bronchofiberscopic examination revealed infiltration of lymphocytes without any malignant cells in the right segment 1 of the lung, which suggested interstitial lung disease...
May 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28367384/pilocytic-astrocytoma-enlargement-following-irradiation-relapse-or-pseudoprogression
#18
Yury Trunin, Andrey V Golanov, Valery V Kostjuchenko, Mikhail Galkin, Alexander N Konovalov
Pilocytic astrocytomas are the most common gliomas (World Health Organization (WHO) grade 1) in children. According to many authors, stereotactic irradiation (radiotherapy and radiosurgery) is an effective method that provides a prolonged, recurrence-free survival in patients who have had partial tumor removal or in patients with an unresectable tumor. We present a case of a patient with midbrain pilocytic astrocytoma that enlarged considerably in the first six months after irradiation and then diminished in size during the next six months without any antitumor treatment...
February 21, 2017: Curēus
https://www.readbyqxmd.com/read/28349351/advanced-mri-techniques-in-the-monitoring-of-treatment-of-gliomas
#19
REVIEW
Harpreet Hyare, Steffi Thust, Jeremy Rees
With advances in treatments and survival of patients with glioblastoma (GBM), it has become apparent that conventional imaging sequences have significant limitations both in terms of assessing response to treatment and monitoring disease progression. Both 'pseudoprogression' after chemoradiation for newly diagnosed GBM and 'pseudoresponse' after anti-angiogenesis treatment for relapsed GBM are well-recognised radiological entities. This in turn has led to revision of response criteria away from the standard MacDonald criteria, which depend on the two-dimensional measurement of contrast-enhancing tumour, and which have been the primary measure of radiological response for over three decades...
March 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28296759/the-diagnostic-performance-of-perfusion-mri-for-differentiating-glioma-recurrence-from-pseudoprogression-a-meta-analysis
#20
Bing Wan, Siqi Wang, Mengqi Tu, Bo Wu, Ping Han, Haibo Xu
BACKGROUND: The purpose of this meta-analysis was to evaluate the diagnostic accuracy of perfusion magnetic resonance imaging (MRI) as a method for differentiating glioma recurrence from pseudoprogression. METHODS: The PubMed, Embase, Cochrane Library, and Chinese Biomedical databases were searched comprehensively for relevant studies up to August 3, 2016 according to specific inclusion and exclusion criteria. The quality of the included studies was assessed according to the quality assessment of diagnostic accuracy studies (QUADAS-2)...
March 2017: Medicine (Baltimore)
keyword
keyword
12545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"